Patents by Inventor Calvin B. Harley

Calvin B. Harley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy
    Publication number: 20230114322
    Abstract: The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
    Type: Application
    Filed: May 24, 2022
    Publication date: April 13, 2023
    Inventors: Calvin B. Harley, Laurence Elias, Jennifer Smith, Mark J. Ratain, Fabio Benedetti
  • Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy
    Publication number: 20220325327
    Abstract: The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
    Type: Application
    Filed: November 23, 2021
    Publication date: October 13, 2022
    Inventors: Calvin B. Harley, Laurence Elias, Jennifer Smith, Mark J. Ratain, Fabio Benedetti
  • Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy
    Publication number: 20210269861
    Abstract: The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
    Type: Application
    Filed: September 23, 2020
    Publication date: September 2, 2021
    Inventors: Calvin B. Harley, Laurence Elias, Jennifer Smith, Mark J. Ratain, Fabio Benedetti
  • Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy
    Publication number: 20190382829
    Abstract: The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
    Type: Application
    Filed: December 20, 2018
    Publication date: December 19, 2019
    Inventors: Calvin B. Harley, Laurence Elias, Jennifer Smith, Mark J. Ratain, Fabio Benedetti
  • Method for identification of sensitivity of a patient to telomerase inhibition therapy
    Patent number: 10196677
    Abstract: The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: February 5, 2019
    Assignee: Geron Corporation
    Inventors: Calvin B. Harley, Laurence Elias, Jennifer Smith, Mark J. Ratain, Fabio Benedetti
  • Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy
    Publication number: 20170298421
    Abstract: The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
    Type: Application
    Filed: February 28, 2017
    Publication date: October 19, 2017
    Inventors: Calvin B. Harley, Laurence Elias, Jennifer Smith, Mark J. Ratain, Fabio Benedetti
  • Method for identification of sensitivity of a patient to telomerase inhibition therapy
    Patent number: 9617583
    Abstract: The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: April 11, 2017
    Assignee: Geron Corporation
    Inventors: Calvin B. Harley, Laurence Elias, Jennifer Smith, Mark J. Ratain, Fabio Benedetti
  • Method for Eliciting an Immune Response to Human Telomerase Reverse Transcriptase
    Publication number: 20160263203
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Application
    Filed: December 30, 2015
    Publication date: September 15, 2016
    Inventors: THOMAS R. CECH, JOACHIM LINGNER, TORU M. NAKAMURA, KAREN B. CHAPMAN, GREGG B. MORIN, CALVIN B. HARLEY, WILLIAM H. ANDREWS
  • Compositions and methods for skin conditioning
    Patent number: 9248088
    Abstract: Methods and cosmetic compositions for conditioning the skin, utilizing as active ingredients selected compounds structurally related to astragenols, cycloastragenols, and/or protopanaxatriols, are provided. Such compounds include those of formulas (I), (II) and (III) described herein.
    Type: Grant
    Filed: June 24, 2004
    Date of Patent: February 2, 2016
    Assignee: TELOMERASE ACTIVATION SCIENCES, INC.
    Inventors: Calvin B. Harley, Allison C. Chin, Tsutomu Akama, Nancy Yuk-yu Ip, Yung-hou Wong
  • Method for Eliciting an Immune Response to Human Telomerase Reverse Transcriptase
    Publication number: 20150250863
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Application
    Filed: February 25, 2014
    Publication date: September 10, 2015
    Applicants: The Regents of the University of Colorado, Geron Corporation
    Inventors: Thomas R. Cech, Joachim Lingner, Toru M. Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy
    Publication number: 20150152488
    Abstract: The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
    Type: Application
    Filed: October 2, 2014
    Publication date: June 4, 2015
    Inventors: Calvin B. Harley, Laurence Elias, Jennifer Smith, Mark J. Ratain, Fabio Benedetti
  • Method for identification of sensitivity of a patient to telomerase inhibition therapy
    Patent number: 8877723
    Abstract: The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: November 4, 2014
    Assignee: Geron Corporation
    Inventors: Calvin B. Harley, Laurence Elias, Jennifer Smith, Mark J. Ratain, Fabio Benedetti
  • Method for eliciting an immune response to human telomerase reverse transcriptase
    Patent number: 8709995
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: April 29, 2014
    Assignees: Geron Corporation, The Regents of the University of Colorado
    Inventors: Thomas R. Cech, Joachim Lingner, Toru M. Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Compositions and methods for increasing telomerase activity
    Patent number: 8481721
    Abstract: The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and for enhancing proliferation of stem and progenitor cells.
    Type: Grant
    Filed: May 17, 2010
    Date of Patent: July 9, 2013
    Assignee: Telomerase Activation Sciences, Inc.
    Inventors: Calvin B. Harley, Soo-Peang Khor, Mahesh Ramaseshan, Premchandran Ramiya, Zhu Zhen Pirot, Steven Fauce, Tong Lin
  • Human telomerase catalytic subunit
    Patent number: 8236774
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: August 7, 2012
    Assignee: Geron Corporation
    Inventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Kit for detection of telomerase reverse transcriptase nucleic acids
    Patent number: 8222392
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: July 17, 2012
    Assignees: Geron Corporation, The Regents of the University of Colorado
    Inventors: Thomas R. Cech, Joachim Lingner, Toru M. Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Assay for Telomerase Activity Using Microfluidic Device
    Publication number: 20120070842
    Abstract: Methods for determining the level of telomerase reverse transcriptase activity in mammalian cells are disclosed. A preferred measuring device is a microfluidic device that includes a spectrophotometer, a fluorescent detector, a fluorescence polarization detector or a scintillation counting device.
    Type: Application
    Filed: May 28, 2010
    Publication date: March 22, 2012
    Inventors: Calvin B. Harley, Hui Wang, Zhu Zhen Pirot
  • Human Telomerase Catalytic Subunit
    Publication number: 20110318832
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Application
    Filed: August 21, 2009
    Publication date: December 29, 2011
    Applicant: Geron Corporation
    Inventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy
    Publication number: 20110263685
    Abstract: The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
    Type: Application
    Filed: October 13, 2009
    Publication date: October 27, 2011
    Applicant: Geron Corporation
    Inventors: Calvin B. Harley, Laurence Elias, Jennifer Smith, Mark J. Ratain, Fabio Benedetti
  • Compositions and Methods for Increasing Telomerase Activity
    Publication number: 20100292197
    Abstract: The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and for enhancing proliferation of stem and progenitor cells.
    Type: Application
    Filed: May 17, 2010
    Publication date: November 18, 2010
    Inventors: Calvin B. Harley, Soo-Peang Khor, Mahesh Ramaseshan, Premchandran Ramiya, Zhu Zhen Pirot, Steven Fauce, Tong Lin